Taiwan’s Biotech Bet: DCB’s Role in Advancing Exosome Therapy

In the bustling hub of Taiwan’s Nangang National Biotechnology Park, the Development Center for Biotechnology (DCB) stands as a linchpin in the nation’s biotech ambitions. For 40 years, DCB has evolved alongside the industry, bridging academia and enterprise to propel Taiwan onto the global stage. At the forefront of this mission is Dr. Tsai-Kun Li, DCB’s Vice President, whose insights into the burgeoning field of exosome and extracellular vesicle (EV) therapies illuminate both Taiwan’s potential and its challenges. In an engaging discussion, Dr. Li outlined how DCB is fostering innovation, navigating regulatory hurdles, and positioning Taiwan as a key player in this transformative biotech frontier.

A Legacy of Collaboration and Adaptation

Since its inception, DCB has been a catalyst for Taiwan’s biotech growth, adapting its focus to meet the industry’s evolving needs. From tackling blood transfusion safety in its early days to licensing herbal-derived medicines for diabetes, DCB has consistently aligned its efforts with national priorities. Today, its sights are set on cutting-edge fields like exosome therapy, a domain brimming with therapeutic promise but fraught with regulatory and scientific complexities.

Dr. Li emphasizes DCB’s role as a facilitator, not a competitor, in this ecosystem. “We are not trying to compete with the industry,” he says. “What is good for DCB is that we have government support to develop the right things and help the industry grow.” This ethos drives DCB’s dual collaboration models: contract services, offering high-quality, low-cost technical support without touching intellectual property, and technology licensing or co-development, where DCB shares platforms or products for early-stage partnerships, with benefits tied to contributions.

Exosomes: A Frontier with Global Stakes

Exosomes and EVs, tiny vesicles that ferry molecular cargo between cells, have sparked global excitement for their potential in treating diseases from cancer to neurodegeneration. In Taiwan, however, the path to clinical application is still being paved. Dr. Li, who has tracked the field’s evolution for over a decade, recalls its academic roots. “The first exosome meeting in Taiwan was hosted in Taoyuan,” he notes, referencing early collaborations with pioneers like Dr. Tang-Long Shen. What began as basic research into cell signaling has now shifted toward practical applications, with Taiwan poised to carve out a niche.

Yet, the journey is far from straightforward. Many Taiwanese companies currently focus on exosome-based cosmetics and nutraceuticals, sidestepping stricter pharmaceutical regulations. Dr. Li sees this as a pragmatic choice but warns of pitfalls. “People are using conditioned media and claiming exosome effects, but without regulation, it’s hard to verify,” he cautions. This trend, driven by shorter payback periods, risks diluting the industry’s credibility if not paired with rigorous standards.

Navigating the Regulatory Maze

The global absence of clear exosome regulations poses both a challenge and an opportunity for Taiwan. While Japan is moving toward defining EVs as biologics, and the U.S. remains in regulatory limbo, Taiwan has a chance to leap ahead by establishing robust frameworks. Dr. Li views this as critical: “If there are no regulations, it’s difficult for agencies to make decisions. We need scientific evidence to define safety and efficacy.”

DCB is actively bridging this gap by leveraging its platforms and fostering dialogue with regulators like the Center for Drug Evaluation (CDE). Dr. Li advocates for a landmark clinical success to set the stage. “We need one case to be clinically proven,” he asserts. “The safety data will start to accumulate, and regulations can follow.” This proof-of-concept (POC) approach, he believes, will galvanize the industry and attract international partners.

That being said, it is apparent that the global exosome market is projected to surge. Li advises Taiwanese biotech firms to start with manageable projects but keep international standards in sight. “Partner with DCB for cost-effective R&D support,” he suggests, “and stay updated on global regulations to ensure alignment.”

Upstream or Downstream? DCB’s Strategic Focus

DCB’s work in exosome development spans two critical phases: upstream, which focuses on producing and isolating exosomes, and downstream, which involves purifying and preparing them for clinical or commercial use. Initially, DCB prioritized upstream processes, helping companies boost exosome yields through optimized cell cultures. However, as global demand for scalable, standardized therapies has intensified, Li notes that DCB has shifted to bolster downstream capabilities, particularly in purification and quality control. “Taiwan’s innovation landscape is changing,” he says, pointing to stricter regulatory standards from bodies like the U.S. FDA and Japan’s PMDA. 

This evolution positions Taiwan to compete with regional powerhouses like Singapore and Japan, where downstream bottlenecks often hinder progress. For companies, Li advises investing early in scalable purification technologies that meet Good Manufacturing Practice (GMP) standards. “Don’t just focus on production,” he cautions. “Build systems that ensure consistency and regulatory compliance.”

Smart Targeting: Avoiding Crowded Markets

Taiwan’s exosome industry needs a catalyst, and Dr. Li believes a single successful clinical case could be the spark. “One win could change everything,” he says, stressing the importance of a “proof of concept” to demonstrate safety and efficacy. Such a breakthrough would unlock funding, bolster regulatory confidence, and spur investment. Li points to “blue ocean” markets—less competitive areas like eye diseases, driven by rising screen use, or joint disorders, tied to aging populations—as prime targets for clinical validation. 

DCB is facilitating this by fostering collaboration between academia, industry, and Taiwan’s Center for Drug Evaluation (CDE). A validated therapy could position Taiwan as a testing ground for innovative treatments, much like Japan’s early strides in regenerative medicine. 

With global competition intensifying, Li advises companies to avoid overcrowded fields like oncology and focus on achievable trials that generate robust safety data. Oncology, despite its allure, is a crowded field where newcomers face steep barriers. “Everybody loves cancer, but the market is very crowded,” he quips. “Work with DCB and CDE to design studies that build trust,” he recommends, underscoring the need for strategic focus.

Neurodegenerative diseases, while promising due to exosomes’ ability to cross the blood-brain barrier, present manufacturing challenges that make them less ideal for initial POCs. “Exosomes can go there, but right now, manufacturing is an issue,” Dr. Li explains. His pragmatic approach underscores the need for strategic focus to maximize Taiwan’s strengths—robust clinical infrastructure, academic talent, and a legacy of precision industries like semiconductors.

To bridge the strategic considerations of market selection with the tactical decisions surrounding product focus, Dr. Li’s insights direct focus at how Taiwan’s exosome industry must balance immediate opportunities with long-term therapeutic ambitions.

Cosmetics vs. Therapeutics: A Strategic Choice or Missed Opportunity?

While global exosome research targets high-value therapeutics, many Taiwanese firms have pivoted toward cosmetics and nutraceuticals, such as anti-aging serums and supplements. Dr. Li views this as a pragmatic move given Taiwan’s regulatory environment, where cosmetics face fewer hurdles. “Cosmetics offer a quicker path to market,” he explains, noting that startups often use these products to generate cash flow for therapeutic R&D. However, he warns that overhyped claims can damage credibility and attract regulatory scrutiny.

Therapeutics, though more challenging, promise far greater rewards in a market dominated by the U.S. and Europe. Taiwan’s regulatory framework for biologics, still in development, lags behind Japan’s proactive EV policies, pushing firms toward less-regulated sectors. Li advises companies in cosmetics to back claims with solid data and those eyeing therapeutics to target niche fields like ophthalmology or joint diseases, where competition is lighter. “Avoid quick wins that compromise trust,” he says, urging a balance between short-term gains and long-term ambition.

A Path to Regional Leadership: Challenges and Opportunities

Taiwan is eyeing a leadership role in exosome CDMO (Contract Development and Manufacturing Organization) services, but the road ahead isn’t without obstacles. Compared to Singapore’s well-funded biotech ecosystem, Taiwan faces tighter capital constraints, is geographically removed from major pharma hubs, and still lacks a clear regulatory framework for exosomes.

Even so, Dr. Li believes Taiwan has a strong hand to play—especially in early-phase clinical research. “Our healthcare system is a goldmine for clinical research,” he says, pointing to efficient patient recruitment and a deep bench of academic talent. Taiwan’s clinical trial infrastructure is particularly suited to Phase I and II studies. DCB is working to further strengthen this advantage by integrating AI and multi-omics (genomics, proteomics, etc.) to support every stage of exosome R&D, from biomarker discovery to scalable manufacturing.

With global demand for CDMO services on the rise, Taiwan could position itself as a cost-effective, high-quality trial destination. Li suggests that policymakers pave the way by implementing exosome-specific regulations and treating EVs (extracellular vesicles) like biologics to streamline approval pathways. For biotech firms, he recommends leveraging DCB’s matchmaking services to build global partnerships. “Collaboration is key to staying competitive,” he emphasizes.

Teaming Up to Boost Biotech Breakthroughs: Taiwan’s Global Edge Lies in Collaboration and Clinical Strength

Taiwan’s world-class medical system and clinical trial capabilities make it an attractive partner for international biotech companies. Dr. Li points to growing global interest, citing recent collaboration with Japan’s Dr. Yu Fujita on idiopathic pulmonary fibrosis. “Why would Fujita come with his product? Taiwan has good practice standards and clinical expertise,” he says, adding that the environment is ideal for early-stage trials.

DCB is actively fostering these partnerships through international matchmaking and technology transfer initiatives. Importantly, they ensure companies maintain control over their intellectual property. “Don’t be scared to collaborate,” Dr. Li urges. “We’re not taking your ideas; we’re helping them get where they need to be.”

This spirit of collaboration—backed by government-supported programs for both institutions and industry—lowers barriers for startups and expands Taiwan’s reach in the global biotech ecosystem.

Building an Ecosystem for the Future

As Taiwan stands at the cusp of exosome innovation, Dr. Li envisions DCB as the architect of a vibrant biotech ecosystem. By integrating academic research, industry needs, and regulatory dialogue, DCB aims to pave a clear path from lab to clinic. “We want to utilize the media to make everything clear and announce it correctly,” he says, reflecting on his goal to elevate public and industry understanding of exosomes’ potential.

The road ahead is not without hurdles—regulatory uncertainty, safety concerns, and global competition loom large. Yet, Dr. Li’s optimism is infectious. “Taiwan’s bioindustry follows the U.S., but if the U.S. hasn’t made a play, we have an opportunity,” he asserts. With DCB’s support, Taiwan is not just keeping pace but aiming to lead, one clinical success at a time.

As the conversation concludes, Dr. Li’s vision lingers: a Taiwan that leverages its scientific heritage and collaborative ethos to redefine biotech’s frontiers. For exosome therapy, the finish line may be in sight, and DCB is ensuring Taiwan crosses it with confidence.

From cultivating a thriving industrial ecosystem to driving long-term government-backed initiatives, Vice President Dr. Tsai-Kun Li highlights DCB’s dedication to doing the right thing—paving the way for the future of biotech. Image: GeneOnline

Author

Bernice Lottering